ABL1 and breast carcinoma: As the reasons behind this selectivity could be beneficial for the treatment of SRC-associated pathologies, we set to investigate the mode of binding of eCF506 to SRC and the molecular phenotype of eCF506-treated breast cancer cells compared with clinical SRC/ABL inhibitors.